ZWI Therapeutics

ZWI Therapeutics develops protein therapeutics using proprietary new polymers based on polycarboxybetaine, offering advantages over traditional PEGylation, such as reduced immunogenicity and preserved pharmacokinetics. Their lead program, ZWI-001, targets hyperuricemia in severe gout and is currently in development.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $10M

Date: 24-Jan-2024

Investors: Co-win Ventures, Sherpa Healthcare Partners

Markets: Biotechnology, Pharmaceuticals

HQ: Waltham, Massachusetts, United States

Founded: 2020

Website: https://www.zwitx.com/

LinkedIn: https://www.linkedin.com/company/zwitx

Twitter:

Instagram: